The independent source for health policy research, polling, and news.
July 22, 2021
In this Axios column, Drew Altman unpacks President Biden’s recent executive order on promoting competition, exploring its significance for new efforts to control health costs by addressing consolidation in the health care industry.
Column Read PostJune 25, 2021
In this Axios column, Drew Altman looks beyond Medicare to what’s at stake for employers and workers in the debate about the government negotiating drug prices.
Column Read PostMay 27, 2021
In this column for the JAMA Health Forum, Larry Levitt examines the implications of lowering Medicare’s age of eligibility, which is emerging as a potential pathway toward Medicare-for-all or a public option among single-payer advocates. He explores the implications for costs, industry, people and broader reform efforts.
Column Read PostMay 26, 2021
With news that the country has now vaccinated half of its population with at least one dose, This Drew Altman Axios column highlights the persistent COVID-19 vaccine myths that are believed by a substantial portion of the unvaccinated population and discusses the options to address vaccine misinformation.
Column Read PostMay 25, 2021
In this op-ed for The Washington Post, Drew Altman suggests a way out of the heated debate about a COVID-19 vaccination passport to help provide clarity about who is vaccinated and who still ought to wear masks in public spaces or the workplace by using something that already exists– CDC vaccination cards.
Op-Ed Read PostApril 29, 2021
In this Axios column, Drew Altman explores whether the long struggle with rising health costs has caused the tide to turn in corporate leaders’ attitudes towards government involvement in controlling health spending and whether it is part of a larger shift in comfort with government action to solve problems.
Column Read Post